相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors
Bjorn Schilstrom et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Galantamine improves cognition in schizophrenic patients stabilized on risperidone
Max H. Schubert et al.
BIOLOGICAL PSYCHIATRY (2006)
Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats
Yan-qi Liang et al.
ACTA PHARMACOLOGICA SINICA (2006)
The schizophrenia cognition rating scale: An interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity
RSE Keefe et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial
O Freudenreich et al.
PSYCHOPHARMACOLOGY (2005)
Efficacy and tolerability of low-dose donepezil in schizophrenia
SK Erickson et al.
CLINICAL NEUROPHARMACOLOGY (2005)
Antipsychotic drug effects on brain morphology in first-episode psychosis
JA Lieberman et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Stability of cognitive performance in older patients with schizophrenia: An 8-week lest-retest study
PD Harvey et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
A summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia.
RW Buchanan et al.
SCHIZOPHRENIA BULLETIN (2005)
A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia
O Tugal et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2004)
Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses
JF Reyes et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Augmenting atypical Antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: A pilot double-blind placebo controlled BOLD fMRI study
Z Nahas et al.
NEUROCASE (2003)
Pharmacokinetic and safety assessments of concurrent administration of risperidone and donepezil
QY Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia
RW Buchanan et al.
SCHIZOPHRENIA RESEARCH (2003)
Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum
J Ichikawa et al.
NEUROPSYCHOPHARMACOLOGY (2002)
Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat
IJ Mitchell et al.
NEUROSCIENCE (2002)
A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia
JI Friedman et al.
BIOLOGICAL PSYCHIATRY (2002)
Neurocognitive and social functioning in schizophrenia and other diagnoses
J Addington et al.
SCHIZOPHRENIA RESEARCH (2001)
Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment
PD Harvey et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
I McKeith et al.
LANCET (2000)
Decreased muscarinic receptor binding in subjects with schizophrenia: A study of the human hippocampal formation
JM Crook et al.
BIOLOGICAL PSYCHIATRY (2000)
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol
SE Purdon et al.
ARCHIVES OF GENERAL PSYCHIATRY (2000)
Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the right stuff?
MF Green et al.
SCHIZOPHRENIA BULLETIN (2000)
分享论文
